FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Utter Christine Marie 		2. Issuer Name and Ticker or Trading Symbol

PTC THERAPEUTICS, INC. [ PTCT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Principal Financial Officer
(Last)          (First)          (Middle)

C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT 		3. Date of Earliest Transaction (MM/DD/YYYY)

6/2/2017
(Street)

SOUTH PLAINFIELD, NJ 07080
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                  5297   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right To Buy)   $13.1   6/2/2017     A      25000         (1) 6/2/2027   Common Stock   25000.0   $0   25000   D    
Stock Option (Right To Buy)   $490.8                      (2) 4/27/2021   Common Stock   74.0     74   D    
Stock Option (Right To Buy)   $218.4                      (2) 1/10/2022   Common Stock   21.0     21   D    
Stock Option (Right To Buy)   $10.85                      (2) 5/15/2023   Common Stock   1150.0     1150   D    
Stock Option (Right To Buy)   $27.05                      (3) 1/28/2024   Common Stock   3369.0     3369   D    
Stock Option (Right To Buy)   $40.45                      (4) 9/23/2024   Common Stock   4688.0     4688   D    
Stock Option (Right To Buy)   $51.0                      (5) 1/2/2025   Common Stock   17800.0     17800   D    
Stock Option (Right To Buy)   $30.86                      (6) 1/3/2026   Common Stock   11000.0     11000   D    
Stock Option (Right To Buy)   $11.23                      (7) 1/2/2027   Common Stock   12600.0     12600   D    

Explanation of Responses:
(1)  This option was granted on June 2, 2017, and vests over two years, with 50% of the shares underlying the option vesting on June 2, 2018, and an additional 12.5% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on September 2, 2018.
(2)  Currently exercisable.
(3)  This option was granted on January 28, 2014 and vests over four years, with 25% of the shares underlying the option vested on January 28, 2015, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 28, 2015.
(4)  This option was granted on September 23, 2014 and vests over four years, with 25% of the shares underlying the option vested on September 23, 2015, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on December 23, 2015.
(5)  This option was granted on January 2, 2015 and vests over four years, with 25% of the shares underlying the option vested on January 2, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2016.
(6)  This option was granted on January 4, 2016 and vests over four years, with 25% of the shares underlying the option vested on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
(7)  This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Utter Christine Marie
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT
SOUTH PLAINFIELD, NJ 07080

Principal Financial Officer

Signatures
Avraham S. Adler, attorney-in-fact 6/6/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
PTC Therapeutics (NASDAQ:PTCT)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more PTC Therapeutics Charts.
PTC Therapeutics (NASDAQ:PTCT)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more PTC Therapeutics Charts.